A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Specified dose on specified days

DRUG

Ipilimumab

Specified dose on specified days

DRUG

BMS-986207

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (71)

0

Local Institution - 0056, Wahroonga

1061

Local Institution - 0062, Buenos Aires

1125

Local Institution - 0021, Buenos Aires

1280

Local Institution - 0011, Buenos Aires

2700

Local Institution - 0009, Pergamino

2800

Local Institution - 0063, Orange

Local Institution - 0034, Mechelen

3010

Local Institution - 0041, Alicante

3280

Local Institution - 0052, Warrnambool

5400

Local Institution - 0057, San Juan

6000

Local Institution - 0040, Charleroi

7000

Local Institution - 0043, Mons

7548

Local Institution - 0017, Gera

9100

Local Institution - 0019, Sint-Niklaas

11220

Local Institution - 0049, Brooklyn

20089

Local Institution - 0020, Rozzano

20133

Local Institution, Milan

20900

Local Institution - 0039, Monza

23007

Local Institution - 0046, Jaén

28040

Local Institution - 0032, Madrid

28220

Local Institution - 0033, Majadahonda

29414

Local Institution - 0012, Charleston

32308

Local Institution, Tallahassee

32504

Local Institution - 0045, Pensacola

32610

Local Institution - 0073, Gainesville

32763

Local Institution - 0036, Orange City

33401

Local Institution, West Palm Beach

33604

Local Institution - 0044, Pessac

33705

Local Institution - 0068, St. Petersburg

33901

Local Institution - 0070, Fort Myers

34010

Local Institution - 0076, Istanbul

34098

Local Institution - 0066, Istanbul

34952

Local Institution, Port Saint Lucie

35128

Local Institution - 0001, Padua

35575

Local Institution - 0065, Izmir

41017

Local Institution - 0074, Edgewood

42271

Local Institution - 0031, Saint-Priest-en-Jarez

44093

Local Institution - 0030, Nantes

48109

Local Institution - 0002, Ann Arbor

53226

Local Institution - 0053, Milwaukee

55200

Local Institution - 0067, Samsun

60590

Local Institution - 0022, Frankfurt am Main

65199

Local Institution - 0059, Wiesbaden

76000

Local Institution - 0016, Rouen

80131

Local Institution - 0028, Naples

81925

Local Institution - 0023, München

82131

Local Institution - 0005, Gauting

83056

Local Institution - 0042, Toulon

83214

Local Institution - 0077, Coeur d'Alene

83706

Local Institution - 0081, Boise

85719

Local Institution - 0080, Tucson

87042

Local Institution - 0037, Limoges

91200

Local Institution - 0078, Jerusalem

Local Institution - 0079, Jerusalem

92150

Local Institution - 0013, Suresnes

92708

Local Institution - 0051, Fountain Valley

2520000

Local Institution - 0035, Viña del Mar

2520598

Local Institution - 0015, Viña del Mar

3339419

Local Institution - 0064, Haifa

8320000

Local Institution - 0050, Santiago

9103102

Local Institution - 0061, Jerusalem

S2000DEJ

Local Institution - 0054, Rosario

C1122

Local Institution - 0048, Buenos Aires

85-796

Local Institution - 0024, Bydgoszcz

93-338

Local Institution - 0003, Lodz

05-400

Local Institution - 0038, Otwock

70-452

Local Institution - 0058, Szczecin

08017

Local Institution - 0026, Barcelona

08028

Local Institution - 0075, Barcelona

08908

Local Institution - 0006, Barcelona

01250

Local Institution - 0072, Yüreğir

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05005273 - A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter